2. Academic Validation
  3. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

  • Leukemia. 2012 Aug;26(8):1892-5. doi: 10.1038/leu.2012.67.
Z-X Cao,  J-J Liu,  R-L Zheng,  J Yang,  L Zhong,  Y Xu,  L-J Wang,  C-H Zhang,  B-L Wang,  S Ma,  Z-R Wang,  H-Z Xie,  Y-Q Wei,  S-Y Yang
PMID: 22402607 DOI: 10.1038/leu.2012.67
Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z